# A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα）

> **NCT07690332** · — · NOT_YET_RECRUITING · sponsor: **NING LI-GYN** · enrollment: 400 (estimated)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancers
- Primary Peritoneal Cancer

## Interventions

- **DRUG:** Mirvetuximab Soravtansine (MIRV)

## Key facts

- **NCT ID:** NCT07690332
- **Lead sponsor:** NING LI-GYN
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-20
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07690332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07690332, "A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα）". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07690332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*